Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||gastric adenocarcinoma||not applicable||Nivolumab + Ramucirumab||Phase Ib/II||Actionable||In a Phase I/II trial, Cyramza (ramucirumab) and Opdivo (nivolumab) combination treatment resulted in a disease control rate of 59% (27/46) and partial response in 22% (10/46) of patients with previously treated advanced gastric adenocarcinoma, with a PD-L1 positive rate of 44% (J Clin Oncol 36, 2018 (suppl; abstr 4047); NCT02999295).||detail...|
|PubMed Id||Reference Title||Details|
|Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).||Full reference...|